Tag: Bill Gates

Steve Bannon Thought Jeffrey Epstein Was a Spy

Tina Marie (Ms. Cat)

Steve Bannon Thought Jeffrey Epstein Was a Spy

Charles Johnson, a conservative provocateur, worked with Bannon at Breitbart News, the right-wing website Bannon led for several years, and also got the impression that Bannon’s visits to Epstein involved the intelligence world. Johnson says that Bannon made several visits to Epstein’s New York mansion after he was ousted from the White House in August 2017. “He also offered to introduce me to him at one point,” Johnson tells Rolling Stone. (Johnson declined the offer.) “What I was told about that meeting by people close to Bannon was that he was trying to replace Epstein as a source for information from various intelligence networks. He saw Epstein as a rival or a partner but he wanted what Epstein had.” Johnson, who says he’s now a Biden supporter, said he has been cooperating with law-enforcement officials investigating Bannon.

…

In recent years, Bannon has become a close to Guo Wengui, a fugitive Chinese billionaire living in New York who has been locked in a dispute with his homeland. Guo has accused Chinese Communist Party officials of corruption; China has accused him of bribery, fraud, and blackmail. At the same time, Guo has been accused by one of his former business partners and a Chinese media star of, among other things, sexual blackmail. According to a lawsuit filed in New York and reports in Toronto’s Globe and Mail newspaper, Guo allegedly used prostitutes and hidden cameras to compromise powerful figures as a means of clout and control. A message sent to Guo’s representative seeking comment was not returned.

Just as he helped elevate Epstein’s status, Bannon has attempted to legitimize Guo. He has served on the boards of companies and nonprofits linked to Guo, some of which are reportedly under federal investigation. He had been living on Guo’s yacht when he was arrested last year for defrauding donors to a group trying to build Trump’s border wall.

Wall Street’s Takeover of Nature Advances with Launch of New Asset Class

Tina Marie (Ms. Cat)

A project of the multilateral development banking system, the Rockefeller Foundation and the New York Stock Exchange recently created a new asset class that will put, not just the natural world, but the processes underpinning all life, up for sale under the guise of promoting “sustainability.”

Wall Street’s Takeover of Nature Advances with Launch of New Asset Class

Conspiracy theories aside, there is something fishy about the Great Reset

Tina Marie (Ms. Cat)

Conspiracy theories aside, there is something fishy about the Great Reset

Instead of corporations serving many stakeholders, in the multi-stakeholder model of global governance, corporations are promoted to being official stakeholders in global decision-making, while governments are relegated to being one of many stakeholders. In practice, corporations become the main stakeholders, while governments take a backseat role, and civil society is mainly window dressing.

Gates, Soros team up on access to medical technology

Tina Marie (Ms. Cat)

Gates, Soros team up on access to medical technology

Mologic Ltd is a world-leading innovator in the development of lateral flow and rapid diagnostic technologies, including tests that can help combat tropical diseases such as dengue, bilharzia, and river blindness – as well as Covid-19

…

The £30 million acquisition was announced in summer 2021 and is being made through the Global Access Health (GAH), a social enterprise. GAH will seek to expand access to affordable state-of-the-art medical technology through decentralized research, development, and manufacturing in and for the Global South. The Soros Economic Development Fund launched the GAH in July with support from several philanthropic funds and investors including the Bill & Melinda Gates Foundation.

Why Is the Gates Foundation Funding the UK’s Medicines Regulator?

Tina Marie (Ms. Cat)

Why Is the Gates Foundation Funding the UK’s Medicines Regulator?

“Safety in a world of user fees” is of paramount concern, concluded Lexchin. That was was back in 2017. Four years on, we are in the biggest health crisis of our lifetimes and the tasks performed by medicines regulators are more important than ever. New experimental vaccines and therapeutic treatments are rolling off the line in record time. But they’re also being authorised in record time — in some cases despite scant evidence of benefits (e.g., Remdesivir). And they’re earning record profits for their manufacturers. At the same time, promising repurposed off-patent medicines that do not offer lucrative financial returns are largely being ignored or are even being demonised by our medicines regulators.